⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
businesswire.com
MRK
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
businesswire.com
MRK
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
businesswire.com
MRK
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
businesswire.com
MRK
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
prnewswire.com
IOVA
MRK
LLY
JNJ
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
businesswire.com
MRK
European Commission Approves KEYTRUDA ® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
businesswire.com
MRK
Merck Announces KEYTRUDA ® (pembrolizumab) Plus WELIREG ® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
businesswire.com
MRK
Merck and Eisai Announce WELIREG ® (belzutifan) Plus LENVIMA ® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
businesswire.com
MRK
U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
businesswire.com
MRK